Cargando…

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients

OBJECTIVE: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huseynzada, Sinakhanım, Yüce İnel, Tuba, Hajiyev, Farid, Köken Avşar, Aydan, Balcı, Ali, Akpınar, Hale, Önen, Fatoş, Sarı, İsmail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mesut Onat 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542484/ https://www.ncbi.nlm.nih.gov/pubmed/37171478 http://dx.doi.org/10.5152/eurjrheum.2023.22049

Ejemplares similares

The effect of COVID-19 pandemic in a large series of patients with Takayasu arteritis
por: KARAKAŞ, Ali, et al.
Publicado: (2022)

Spontaneous Remission of Isaacs’ Syndrome
por: Uslu, Sadettin, et al.
Publicado: (2019)

Sacroiliac joint involvement in ochronotic arthropathy
por: Yüce İnel, Tuba, et al.
Publicado: (2021)

Shrinking Lung Syndrome in Primary Sjögren Syndrome
por: Uslu, Sadettin, et al.
Publicado: (2020)

Bullous drug eruption with low dose methotrexate
por: Yuce Inel, Tuba
Publicado: (2021)

High prevalence of spondyloarthritis and ankylosing spondylitis among familial Mediterranean fever patients and their first-degree relatives: further evidence for the connection
por: Akar, Servet, et al.
Publicado: (2013)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

A preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients
por: Koçak, Ayşe, et al.
Publicado: (2021)

Increased Levels of Macrophage Migration Inhibitory Factor in Patients with Familial Mediterranean Fever
por: Savran, Yusuf, et al.
Publicado: (2013)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

A Case of Adult-Onset Still's Disease Complicated with Diffuse Alveolar Hemorrhage
por: Sari, Ismail, et al.
Publicado: (2009)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life
por: Ozer, Muhammet, et al.
Publicado: (2020)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
por: Luzentales-Simpson, Matthew, et al.
Publicado: (2021)

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
por: Wyant, Timothy, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study
por: Tuylu, Tugba, et al.
Publicado: (2014)

Determinants of Six-Minute Walk Test Performance in Women with Systemic Sclerosis
por: Sezgin, Nazenin Hande, et al.
Publicado: (2023)

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
por: Scribano, Maria Lia
Publicado: (2018)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
por: Ward, Mark G., et al.
Publicado: (2018)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qm14vhmh4d544girf4v1drlgp9